Izervay is a drug owned by Astellas Pharma Us Inc. It is protected by 9 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 11, 2034. Details of Izervay's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9617546 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(2 months from now) | Active |
| US10947544 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(2 months from now) | Active |
| US7803931 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(2 months from now) | Active |
| US7538211 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(2 months from now) | Active |
| US7579456 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(2 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11491176 | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(9 years from now) | Active |
| US11273171 | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(9 years from now) | Active |
| US12016875 | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(9 years from now) | Active |
| US8236773 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Nov, 2026
(1 year, 11 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Izervay's patents.
Latest Legal Activities on Izervay's Patents
Given below is the list of recent legal activities going on the following patents of Izervay.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Initial letter Re: PTE Application to regulating agency | 26 Mar, 2024 | US8236773 |
| Initial letter Re: PTE Application to regulating agency | 26 Mar, 2024 | US9617546 |
| Initial letter Re: PTE Application to regulating agency | 26 Mar, 2024 | US7579456 |
| Initial letter Re: PTE Application to regulating agency | 26 Mar, 2024 | US11273171 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236773 |
| Patent Term Extension Application under 35 USC 156 Filed | 27 Sep, 2023 | US11273171 |
| Patent Term Extension Application under 35 USC 156 Filed | 27 Sep, 2023 | US9617546 |
| Patent Term Extension Application under 35 USC 156 Filed | 27 Sep, 2023 | US7579456 |
| Patent Term Extension Application under 35 USC 156 Filed | 27 Sep, 2023 | US8236773 |
| Post Issue Communication - Certificate of Correction | 15 Sep, 2023 | US11273171 |
US patents provide insights into the exclusivity only within the United States, but Izervay is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Izervay's family patents as well as insights into ongoing legal events on those patents.
Izervay's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Izervay's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 11, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Izervay Generics:
There are no approved generic versions for Izervay as of now.
About Izervay
Izervay is a drug owned by Astellas Pharma Us Inc. It is used for treating geographic atrophy secondary to age-related macular degeneration. Izervay uses Avacincaptad Pegol Sodium as an active ingredient. Izervay was launched by Astellas in 2023.
Approval Date:
Izervay was approved by FDA for market use on 04 August, 2023.
Active Ingredient:
Izervay uses Avacincaptad Pegol Sodium as the active ingredient. Check out other Drugs and Companies using Avacincaptad Pegol Sodium ingredient
Treatment:
Izervay is used for treating geographic atrophy secondary to age-related macular degeneration.
Dosage:
Izervay is available in solution form for intravitreal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | SOLUTION | Prescription | INTRAVITREAL |